

Carola Rong

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3069764/publications.pdf>

Version: 2024-02-01

21
papers

748
citations

759233

12
h-index

794594

19
g-index

21
all docs

21
docs citations

21
times ranked

1303
citing authors

#	ARTICLE	IF	CITATIONS
1	Recognition and Treatment of Cognitive Dysfunction in Major Depressive Disorder. <i>Frontiers in Psychiatry</i> , 2018, 9, 655.	2.6	150
2	Cognitive impairment in major depressive disorder. <i>CNS Spectrums</i> , 2019, 24, 22-29.	1.2	125
3	Cannabidiol in medical marijuana: Research vistas and potential opportunities. <i>Pharmacological Research</i> , 2017, 121, 213-218.	7.1	102
4	Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder. <i>International Journal of Environmental Research and Public Health</i> , 2018, 15, 771.	2.6	80
5	Drug-drug interactions as a result of co-administering Δ^9 -THC and CBD with other psychotropic agents. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 51-54.	2.4	64
6	Cognitive impairment as measured by the THINC-integrated tool (THINC-it): Association with psychosocial function in major depressive disorder. <i>Journal of Affective Disorders</i> , 2017, 222, 14-20.	4.1	39
7	Therapeutic potential of JAK/STAT pathway modulation in mood disorders. <i>Reviews in the Neurosciences</i> , 2018, 30, 1-7.	2.9	35
8	Determinants of cognitive function in individuals with type 2 diabetes mellitus: A meta-analysis. <i>Annals of Clinical Psychiatry</i> , 2018, 30, 38-50.	0.6	28
9	Serum metabolic profiling using small molecular water-soluble metabolites in individuals with schizophrenia: A longitudinal study using a pre-post-treatment design. <i>Psychiatry and Clinical Neurosciences</i> , 2019, 73, 100-108.	1.8	20
10	Rapastinel - an investigational NMDA-R modulator for major depressive disorder: evidence to date. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 113-119.	4.1	20
11	Pharmacological Treatment of Cognitive Symptoms in Major Depressive Disorder. <i>CNS and Neurological Disorders - Drug Targets</i> , 2018, 16, 891-899.	1.4	18
12	Ecological momentary assessment of depressive symptoms using the mind.me application: Convergence with the Patient Health Questionnaire-9 (PHQ-9). <i>Journal of Psychiatric Research</i> , 2021, 135, 311-317.	3.1	15
13	Pharmacodynamic and pharmacokinetic evaluation of buprenorphine + samidorphan for the treatment of major depressive disorder. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 475-482.	3.3	12
14	Cognitive impairment as measured by the THINC-integrated tool (THINC-it): The association with self-reported anxiety in Major Depressive Disorder. <i>Journal of Affective Disorders</i> , 2018, 238, 228-232.	4.1	11
15	The use of brexpiprazole amongst individuals with insufficient outcomes with aripiprazole or bupropion: A case series. <i>Perspectives in Psychiatric Care</i> , 2018, 54, 507-513.	1.9	9
16	Intracellular Signaling Cascades in Bipolar Disorder. <i>Current Topics in Behavioral Neurosciences</i> , 2020, 48, 101-132.	1.7	9
17	Does obesity and diabetes mellitus metastasize to the brain? "Metapoptosis" and implications for drug discovery and development. <i>CNS Spectrums</i> , 2019, 24, 467-469.	1.2	5
18	The role of lithium treatment on comorbid anxiety symptoms in patients with bipolar depression. <i>Journal of Affective Disorders</i> , 2022, 308, 71-75.	4.1	4

#	ARTICLE	IF	CITATIONS
19	A case of mirror image agnosia and mirrored self-misidentification syndrome in schizophrenia without dementia or structural abnormalities. <i>Neurocase</i> , 2020, 26, 317-319.	0.6	1
20	A Novel Refractory Mood Disorders and Electroconvulsive Therapy Elective for Medical Students: Fighting Stigma through Experience. <i>Psychiatric Quarterly</i> , 2021, 92, 1541-1548.	2.1	1
21	13-Month maintenance ECT treatment in a 66-year-old male patient with pacemaker. , 2022, 1, 100005.		0